MCID: WRN001
MIFTS: 70

Werner Syndrome

Categories: Genetic diseases, Rare diseases, Eye diseases, Skin diseases, Fetal diseases

Aliases & Classifications for Werner Syndrome

MalaCards integrated aliases for Werner Syndrome:

Name: Werner Syndrome 53 12 23 49 24 55 71 36 28 13 51 41 14 69
Werner's Syndrome 12 72 49 24
Adult Progeria 12 24 55
Wrn 53 49 71
Ws 12 24 55
Adult Premature Ageing Syndrome 12
Adult Premature Aging Syndrome 24
Werners Syndrome 24
Wes 72

Characteristics:

Orphanet epidemiological data:

55
werner syndrome
Inheritance: Autosomal recessive; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Japan),1-9/100000; Age of onset: Adolescent,Adult;

OMIM:

53
Inheritance:
autosomal recessive


HPO:

31
werner syndrome:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Werner Syndrome

NIH Rare Diseases : 49 Werner's syndrome is a disease chiefly characterized by premature aging and cancer predisposition. Development is typically normal until the end of the first decade; the first sign is the lack of a growth spurt during puberty. Early signs (usually in the 20s) include loss and graying of hair, hoarseness, and scleroderma-like skin changes, followed by cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s. Myocardial infarction (heart attack) and cancer are the most common causes of death, which typically occurs in the late 40s. It is caused by mutations in the WRN gene and is inherited in an autosomal recessive manner. Management focuses on treatment of signs and symptoms and prevention of secondary complications. Last updated: 4/29/2011

MalaCards based summary : Werner Syndrome, also known as werner's syndrome, is related to atypical werner syndrome and aging, and has symptoms including joint stiffness, hypertension and cataract. An important gene associated with Werner Syndrome is WRN (Werner Syndrome RecQ Like Helicase), and among its related pathways/superpathways are Cell Cycle, Mitotic and Regulation of TP53 Activity. The drugs Furosemide and Methyltestosterone have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and cellular

UniProtKB/Swiss-Prot : 71 Werner syndrome: A rare autosomal recessive progeroid syndrome characterized by the premature onset of multiple age-related disorders, including atherosclerosis, cancer, non-insulin-dependent diabetes mellitus, ocular cataracts and osteoporosis. The major cause of death, at a median age of 47, is myocardial infarction.

Genetics Home Reference : 24 Werner syndrome is characterized by the dramatic, rapid appearance of features associated with normal aging. Individuals with this disorder typically grow and develop normally until they reach puberty. Affected teenagers usually do not have a growth spurt, resulting in short stature. The characteristic aged appearance of individuals with Werner syndrome typically begins to develop when they are in their twenties and includes graying and loss of hair; a hoarse voice; and thin, hardened skin. They may also have a facial appearance described as "bird-like." Many people with Werner syndrome have thin arms and legs and a thick trunk due to abnormal fat deposition.

Disease Ontology : 12 An autosomal recessive disease characterized by premature aging and age-related phenotypes such as atherosclerosis, arteriosclerosis, cataracts, osteoporosis, soft tissue calcification, premature thinning, graying, and loss of hair, as well as a high incidence of some types of cancers. In 90% of the cases it is that has material basis in mutations in the WRN gene, on chromosome 8.

Wikipedia : 72 Werner syndrome (WS), also known as \"adult progeria\", is a rare, autosomal recessive disorder which is... more...

Description from OMIM: 277700
GeneReviews: NBK1514

Related Diseases for Werner Syndrome

Diseases related to Werner Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 atypical werner syndrome 34.0 LMNA WRN
2 aging 30.7 LMNA PARP1 WRN
3 rothmund-thomson syndrome 28.6 BLM HELLS RECQL RECQL4 RECQL5 WRN
4 bloom syndrome 28.4 BLM FEN1 HELLS RECQL RECQL4 RECQL5
5 fanconi anemia, complementation group a 28.1 BLM FEN1 HELLS LMNA MRE11 PARP1
6 williams-beuren syndrome 12.0
7 waardenburg syndrome, type 2e 11.7
8 disease of mental health 11.5
9 obsessive-compulsive disorder 11.3
10 hutchinson-gilford progeria syndrome 11.2
11 soft tissue sarcoma 10.9
12 uterus bicornis bicollis with partial vaginal septum and unilateral hematocolpos with ipsilateral renal agenesis 10.9
13 adermatoglyphia 10.2 BLM WRN
14 multiple mitochondrial dysfunctions syndrome 5 10.1
15 spondylosis 10.0 HELLS WRN
16 meningioma, familial 10.0
17 diabetes mellitus 9.9
18 autosomal dominant limb-girdle muscular dystrophy 9.9 LMNA VCP
19 osteoporosis 9.9
20 ataxia-telangiectasia 9.9
21 ataxia and polyneuropathy, adult-onset 9.9
22 bone mineral density quantitative trait locus 8 9.9
23 bone mineral density quantitative trait locus 15 9.9
24 melanoma 9.9
25 arteries, anomalies of 9.8
26 immunodeficiency-centromeric instability-facial anomalies syndrome 1 9.8
27 cataract 9.8
28 coronary artery anomaly 9.8
29 sarcoma 9.8
30 hyperglycemia 9.8
31 thyroiditis 9.8
32 atrial standstill 1 9.6
33 blood group, i system 9.6
34 breast cancer 9.6
35 colorectal cancer 9.6
36 fibrosis of extraocular muscles, congenital, 1 9.6
37 endosteal hyperostosis, autosomal dominant 9.6
38 hypertriglyceridemia, familial 9.6
39 retinal detachment 9.6
40 down syndrome 9.6
41 tangier disease 9.6
42 lung cancer 9.6
43 chondrosarcoma 9.6
44 pancreatic cancer 9.6
45 xeroderma pigmentosum, variant type 9.6
46 body mass index quantitative trait locus 11 9.6
47 fragile x syndrome 9.6
48 body mass index quantitative trait locus 9 9.6
49 body mass index quantitative trait locus 8 9.6
50 body mass index quantitative trait locus 4 9.6

Graphical network of the top 20 diseases related to Werner Syndrome:



Diseases related to Werner Syndrome

Symptoms & Phenotypes for Werner Syndrome

Symptoms via clinical synopsis from OMIM:

53
EndocrineFeatures:
diabetes mellitus
hypogonadism

Skeletal:
osteoporosis

HeadAndNeckEyes:
retinal degeneration
cataracts

HeadAndNeckNose:
beaked nose

HeadAndNeckFace:
prematurely aged face

SkinNailsHairHair:
thin, sparse, gray
premature balding

LaboratoryAbnormalities:
variegated translocation mosaicism in cultured fibroblasts
poor mitogenic response to growth factors

GrowthHeight:
short stature

SkinNailsHairSkin:
subcutaneous calcification
scleroderma-like skin, especially of face and distal extremities
ulceration

CardiovascularHeart:
premature arteriosclerosis

GrowthOther:
stocky trunk

SkeletalLimbs:
slender limbs

Neoplasia:
malignancy in approximately 10%
osteosarcoma and meningioma especially


Clinical features from OMIM:

277700

Human phenotypes related to Werner Syndrome:

55 31 (show top 50) (show all 65)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 joint stiffness 55 31 occasional (7.5%) Occasional (29-5%) HP:0001387
2 hypertension 55 31 occasional (7.5%) Occasional (29-5%) HP:0000822
3 cataract 55 31 hallmark (90%) Very frequent (99-80%) HP:0000518
4 type ii diabetes mellitus 55 31 frequent (33%) Frequent (79-30%) HP:0005978
5 short stature 55 31 hallmark (90%) Very frequent (99-80%) HP:0004322
6 abnormality of retinal pigmentation 55 31 frequent (33%) Frequent (79-30%) HP:0007703
7 osteoporosis 55 31 hallmark (90%) Very frequent (99-80%) HP:0000939
8 laryngomalacia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001601
9 lipoatrophy 55 31 hallmark (90%) Very frequent (99-80%) HP:0100578
10 skeletal muscle atrophy 55 31 frequent (33%) Frequent (79-30%) HP:0003202
11 myocardial infarction 55 31 frequent (33%) Frequent (79-30%) HP:0001658
12 hyperkeratosis 55 31 frequent (33%) Frequent (79-30%) HP:0000962
13 abnormality of the thorax 55 31 hallmark (90%) Very frequent (99-80%) HP:0000765
14 congestive heart failure 55 31 frequent (33%) Frequent (79-30%) HP:0001635
15 lack of skin elasticity 55 31 frequent (33%) Frequent (79-30%) HP:0100679
16 secondary amenorrhea 55 31 occasional (7.5%) Occasional (29-5%) HP:0000869
17 skin ulcer 55 31 frequent (33%) Frequent (79-30%) HP:0200042
18 hypogonadism 55 31 hallmark (90%) Very frequent (99-80%) HP:0000135
19 premature graying of hair 55 31 hallmark (90%) Very frequent (99-80%) HP:0002216
20 small hand 55 31 frequent (33%) Frequent (79-30%) HP:0200055
21 telangiectasia of the skin 55 31 frequent (33%) Frequent (79-30%) HP:0100585
22 abnormality of the cerebral vasculature 55 31 occasional (7.5%) Occasional (29-5%) HP:0100659
23 slender build 55 31 hallmark (90%) Very frequent (99-80%) HP:0001533
24 narrow face 55 31 frequent (33%) Frequent (79-30%) HP:0000275
25 aplasia/hypoplasia of the skin 55 31 frequent (33%) Frequent (79-30%) HP:0008065
26 sarcoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0100242
27 abnormality of the voice 55 31 hallmark (90%) Very frequent (99-80%) HP:0001608
28 decreased fertility 55 31 frequent (33%) Frequent (79-30%) HP:0000144
29 sparse scalp hair 55 31 hallmark (90%) Very frequent (99-80%) HP:0002209
30 increased bone mineral density 55 31 frequent (33%) Frequent (79-30%) HP:0011001
31 convex nasal ridge 55 31 hallmark (90%) Very frequent (99-80%) HP:0000444
32 breast carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0003002
33 ovarian neoplasm 55 31 occasional (7.5%) Occasional (29-5%) HP:0100615
34 meningioma 55 31 occasional (7.5%) Occasional (29-5%) HP:0002858
35 pulmonary artery stenosis 55 31 frequent (33%) Frequent (79-30%) HP:0004415
36 white forelock 55 31 hallmark (90%) Very frequent (99-80%) HP:0002211
37 gastrointestinal carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0002672
38 neoplasm of the lung 55 31 occasional (7.5%) Occasional (29-5%) HP:0100526
39 neoplasm of the small intestine 55 31 occasional (7.5%) Occasional (29-5%) HP:0100833
40 chondrocalcinosis 55 31 frequent (33%) Frequent (79-30%) HP:0000934
41 atherosclerosis 55 31 frequent (33%) Frequent (79-30%) HP:0002621
42 squamous cell carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0002860
43 rocker bottom foot 55 31 frequent (33%) Frequent (79-30%) HP:0001838
44 thyroid carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0002890
45 renal neoplasm 55 31 occasional (7.5%) Occasional (29-5%) HP:0009726
46 insulin resistance 55 31 frequent (33%) Frequent (79-30%) HP:0000855
47 pili torti 55 31 hallmark (90%) Very frequent (99-80%) HP:0003777
48 abnormal hair whorl 55 31 hallmark (90%) Very frequent (99-80%) HP:0010721
49 subcutaneous calcification 55 31 frequent (33%) Frequent (79-30%) HP:0007618
50 aplasia/hypoplasia of the testes 55 31 frequent (33%) Frequent (79-30%) HP:0010468

GenomeRNAi Phenotypes related to Werner Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.36 BLM EXO1 FEN1 MRE11 PARP1 RECQL

MGI Mouse Phenotypes related to Werner Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 BLM DHX9 EXO1 FEN1 HELLS LMNA
2 hematopoietic system MP:0005397 10.17 HELLS LMNA MRE11 PARP1 POLB RECQL4
3 immune system MP:0005387 10.1 BLM DHX9 EXO1 FEN1 HELLS LMNA
4 growth/size/body region MP:0005378 10.07 BLM FEN1 HELLS LMNA PARP1 POLB
5 embryo MP:0005380 10.03 BLM DHX9 FEN1 HELLS MRE11 PARP1
6 endocrine/exocrine gland MP:0005379 10.01 EXO1 FEN1 HELLS LMNA POLB RECQL4
7 digestive/alimentary MP:0005381 9.93 XRCC5 FEN1 LMNA POLB RECQL4 WRN
8 mortality/aging MP:0010768 9.8 HELLS LMNA MRE11 PARP1 POLB RECQL4
9 integument MP:0010771 9.76 LMNA PARP1 POLB RECQL4 VCP WRN
10 neoplasm MP:0002006 9.23 BLM EXO1 FEN1 MRE11 RECQL4 RPA1

Drugs & Therapeutics for Werner Syndrome

Drugs for Werner Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 394)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
2
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
3
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
4
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
5
Pantoprazole Approved Phase 4 102625-70-7 4679
6
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
7
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 1 38396-39-3, 2180-92-9 2474
8
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
9
Zoledronic acid Approved Phase 4 118072-93-8 68740
10
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
11
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
12
Warfarin Approved Phase 4 81-81-2 54678486 6691
13
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
14
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
15 Defibrotide Approved, Investigational Phase 4 83712-60-1
16
Verapamil Approved Phase 4 52-53-9 2520
17
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
18
Phytonadione Approved, Investigational, Nutraceutical Phase 4 84-80-0 5284607 4812
19 diuretics Phase 4
20 Natriuretic Agents Phase 4
21 Sodium Potassium Chloride Symporter Inhibitors Phase 4
22 Anabolic Agents Phase 4,Phase 3,Phase 2
23 Androgens Phase 4,Phase 3,Phase 2
24 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2
29
Testosterone enanthate Phase 4,Phase 3,Phase 2 315-37-7 9416
30 Testosterone undecanoate Phase 4,Phase 3,Phase 2
31 Gastrointestinal Agents Phase 4,Phase 2
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Micronutrients Phase 4,Phase 3
35 Trace Elements Phase 4,Phase 3
36 Vitamins Phase 4
37 Narcotic Antagonists Phase 4,Phase 2,Phase 1
38 Narcotics Phase 4,Phase 2,Phase 1
39 Antacids Phase 4
40 Anti-Ulcer Agents Phase 4
41 Proton pump inhibitors Phase 4
42 Autonomic Agents Phase 4,Phase 2
43 Dopamine Agents Phase 4,Phase 2
44 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Anesthetics Phase 4,Phase 3,Phase 1
46 Anesthetics, Local Phase 4,Phase 3,Phase 1
47 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
48 Bone Density Conservation Agents Phase 4,Phase 3
49 Anticoagulants Phase 4,Phase 3
50 Antifibrinolytic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 278)

# Name Status NCT ID Phase Drugs
1 Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers Unknown status NCT01156220 Phase 4 Furosemide;aminohippurate sodium
2 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Unknown status NCT01699178 Phase 4 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
3 Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study Unknown status NCT00546845 Phase 4
4 Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
5 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
6 Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342) Completed NCT00325676 Phase 4 Pantoprazole
7 Donor Dopamine and Initial Graft Function Completed NCT00115115 Phase 4 Dopamine infusion to brain dead organ donors
8 Pain Reduction After Cholecystectomy Completed NCT01199406 Phase 4 Levobupivacaine
9 Pacing of the Atria in Sick Sinus Syndrome Trial Preventive Strategies for Atrial Fibrillation Completed NCT00161538 Phase 4
10 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
11 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
12 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? Recruiting NCT02806440 Phase 4 Low dose naltrexone;Placebo
13 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
14 Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants Recruiting NCT02573012 Phase 4 Placebo matched to prednisone;Prednisone
15 Defibrotide in the Human Endotoxemia Model --‐ an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide Recruiting NCT02876601 Phase 4 Defibrotide;Placebo (0.9% sodium chloride);Lipopolysaccharide
16 Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation Recruiting NCT02067182 Phase 4 Dabigatran
17 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
18 Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years Unknown status NCT00546988 Phase 3
19 Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Unknown status NCT00055874 Phase 3 cytarabine;hydroxyurea;imatinib mesylate
20 F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets Unknown status NCT00882609 Phase 3
21 Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery Completed NCT01219881 Phase 3 Desflurane;Sevoflurane
22 Bladder Scan of Residual Urine With New Catheter Completed NCT01048541 Phase 2, Phase 3
23 Trigger-point Blockade in Persistent Pain After Laparoscopical Groin Hernia Repair Completed NCT02065804 Phase 3 Bupivacaine
24 Trigger-point Blockade in Persistent Pain After Open Groin Hernia Repair Completed NCT02065219 Phase 3 Bupivacaine;Placebo
25 Bosentan for Mild Pulmonary Vascular Disease in Asd Patients. Completed NCT01218607 Phase 3 Bosentan;Placebo
26 Comparing Two Forms of Head Immobilization for Stereotactic Radiotherapy Completed NCT00328510 Phase 3
27 Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Completed NCT01120301 Phase 3
28 Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer Completed NCT00030732 Phase 3 Gemcitabine + Capecitabine;Gemcitabine alone
29 Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007) Completed NCT00074906 Phase 3 Venticute
30 Study About Efficacy and Safety to Treat Multi-System-Atrophy Completed NCT00146809 Phase 3 Minocyline
31 Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus Completed NCT00955799 Phase 3 Neramexane mesylate;Placebo
32 Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus Completed NCT00739635 Phase 3 Neramexane mesylate;Placebo
33 Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men Completed NCT01403116 Phase 3 oral testosterone undecanoate;topical testosterone gel 1%
34 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
35 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
36 Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) Completed NCT00106691 Phase 3 Toremifene 20 mg;Placebo
37 Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer Completed NCT00036556 Phase 3 Atrasentan
38 Study to Investigate Efficacy and Safety of a New Oral Contraceptive Completed NCT00185289 Phase 3 EV/DNG (Qlaira, BAY86-5027, SH T00658K)
39 Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes Completed NCT00860288 Phase 2, Phase 3 Vildagliptin;Metformin;Placebo;Sitagliptin
40 Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Recruiting NCT00632853 Phase 3 cisplatin;etoposide;carboplatin
41 BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction Recruiting NCT01569178 Phase 3
42 Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Recruiting NCT01368588 Phase 3
43 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
44 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) Recruiting NCT03057977 Phase 3 Empagliflozin;Placebo
45 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) Recruiting NCT03057951 Phase 3 Empagliflozin;Placebo
46 Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC Recruiting NCT02273375 Phase 3 MEDI4736;Placebo
47 Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Recruiting NCT01993810 Phase 3 paclitaxel;carboplatin;etoposide;cisplatin
48 Apixaban for Treatment of Embolic Stroke of Undetermined Source Recruiting NCT02427126 Phase 3 Apixaban;Aspirin
49 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Recruiting NCT02115282 Phase 3 Entinostat;Exemestane;Goserelin Acetate
50 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel

Search NIH Clinical Center for Werner Syndrome

Cochrane evidence based reviews: werner syndrome

Genetic Tests for Werner Syndrome

Genetic tests related to Werner Syndrome:

# Genetic test Affiliating Genes
1 Werner Syndrome 28 WRN

Anatomical Context for Werner Syndrome

MalaCards organs/tissues related to Werner Syndrome:

38
Skin, Lung, Heart, Prostate, Bone, Kidney, Brain

Publications for Werner Syndrome

Articles related to Werner Syndrome:

(show top 50) (show all 476)
# Title Authors Year
1
Werner syndrome (WRN) gene variants and their association with altered function and age-associated diseases. ( 29146545 )
2018
2
Folate modulates guanine-quadruplex frequency and DNA damage in Werner syndrome. ( 29412869 )
2018
3
Transcatheter aortic valve replacement in a patient with Werner syndrome. ( 28631398 )
2017
4
Genome-wide DNA methylation analysis in blood cells from patients with Werner syndrome. ( 28861129 )
2017
5
Nailfold scleroderma-like capillary abnormalities in Werner syndrome (adult progeria). ( 28466674 )
2017
6
Recent Advances in Understanding Werner Syndrome. ( 29043077 )
2017
7
The Werner Syndrome Helicase Coordinates Sequential Strand Displacement and FEN1-Mediated Flap Cleavage during Polymerase I' Elongation. ( 27849570 )
2017
8
Case of Werner syndrome complicated by adrenal insufficiency due to hypothalamic dysfunction. ( 28240455 )
2017
9
Cognitive deficit in hippocampal-dependent tasks in Werner syndrome mouse model. ( 28119126 )
2017
10
Accelerated epigenetic aging in Werner syndrome. ( 28377537 )
2017
11
Recent Trends in WRN Gene Mutation Patterns in Individuals with Werner Syndrome. ( 28394436 )
2017
12
Femoral osteoporosis is more common than lumbar osteoporosis in patients with Werner syndrome. ( 28508498 )
2017
13
Homozygosity for the WRN Helicase-Inactivating Variant, R834C, does not confer a Werner syndrome clinical phenotype. ( 28276523 )
2017
14
Residues in the RecQ C-terminal Domain of the Human Werner Syndrome Helicase are Involved in Unwinding G-quadruplex DNA. ( 28069813 )
2017
15
Do you know this syndrome? Werner syndrome. ( 28538897 )
2017
16
A novel splice-site mutation of WRN (c.IVS28+2T>C) identified in a consanguineous family with Werner Syndrome. ( 28440507 )
2017
17
Werner syndrome: a model for sarcopenia due to accelerated aging. ( 28738022 )
2017
18
Uncommon cause of cirrhosis-A case of Werner syndrome with a novel WRN mutation. ( 28795391 )
2017
19
The Relationship between Werner Syndrome and Sinonasal Malignant Melanoma: Two Sibling Cases of Werner Syndrome with Malignant Melanoma. ( 28717528 )
2017
20
Werner Syndrome and Diabetes Mellitus Accompanied by Adrenal Cortex Cancer. ( 28768969 )
2017
21
WRN, the Werner Syndrome Gene, Exhibits Frameshift Mutations in Gastric and Colorectal Cancers. ( 28012115 )
2016
22
Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts. ( 27136566 )
2016
23
Increased susceptibility to oxidative stress- and ultraviolet A-induced apoptosis in fibroblasts in atypical progeroid syndrome/atypical Werner syndrome with LMNA mutation. ( 27539898 )
2016
24
Vitamin C alleviates aging defects in a stem cell model for Werner syndrome. ( 27271327 )
2016
25
Active Control of Repetitive Structural Transitions between Replication Forks and Holliday Junctions by Werner Syndrome Helicase. ( 27427477 )
2016
26
Werner syndrome through the lens of tissue and tumour genomics. ( 27559010 )
2016
27
The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells. ( 26611938 )
2016
28
The Werner syndrome RECQ helicase targets G4 DNA in human cells to modulate transcription. ( 26984941 )
2016
29
Adult Progeria: Werner Syndrome. ( 27734655 )
2016
30
Inflammageing assessed by MMP9 in normal Japanese individuals and the patients with Werner syndrome. ( 27195193 )
2016
31
The Caenorhabditis elegans Werner syndrome protein participates in DNA damage checkpoint and DNA repair in response to CPT-induced double-strand breaks. ( 26691982 )
2016
32
Case of sarcomatoid carcinoma occurring in a patient with Werner syndrome. ( 27074772 )
2016
33
Improved Glycemic Control and Vascular Function and Reduction of Abdominal Fat Accumulation with Liraglutide in a Case of Werner Syndrome with Diabetes Mellitus. ( 27000366 )
2016
34
Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions. ( 26993153 )
2016
35
Radiographic presentation of musculoskeletal involvement in Werner syndrome (adult progeria). ( 27931782 )
2016
36
Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. ( 25931448 )
2015
37
Werner Syndrome with Heart Block. ( 26071823 )
2015
38
WRN protein as a novel erythroblast immunohistochemical marker with applications for the diagnosis of Werner syndrome. ( 25503078 )
2015
39
Methylation of Werner syndrome protein is associated with the occurrence and development of invasive meningioma via the regulation of Myc and p53 expression. ( 26622343 )
2015
40
Association of the rs1346044 Polymorphism of the Werner Syndrome Gene RECQL2 with Increased Risk and Premature Onset of Breast Cancer. ( 26690424 )
2015
41
Epigenetic Regulation of Werner Syndrome Gene in Age-Related Cataract. ( 26509079 )
2015
42
Astaxanthin Improves Nonalcoholic Fatty Liver Disease in Werner Syndrome with Diabetes Mellitus. ( 26096415 )
2015
43
A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies. ( 25830902 )
2015
44
Multiplex cytokine analysis of Werner syndrome. ( 26668779 )
2015
45
POLD1 Germline Mutations in Patients Initially Diagnosed with Werner Syndrome. ( 26172944 )
2015
46
Werner Syndrome-specific induced pluripotent stem cells: recovery of telomere function by reprogramming. ( 25688260 )
2015
47
Impact of vitamin C on the cardiometabolic and inflammatory profiles of mice lacking a functional Werner syndrome protein helicase. ( 26521679 )
2015
48
A missense single nucleotide polymorphism, V114I of the Werner syndrome gene, is associated with risk of osteoporosis and femoral fracture in the Japanese population. ( 25637295 )
2015
49
Microwave-Assisted Synthesis of a MK2 Inhibitor by Suzuki-Miyaura Coupling for Study in Werner Syndrome Cells. ( 26046488 )
2015
50
Metabolic and Phenotypic Differences between Mice Producing a Werner Syndrome Helicase Mutant Protein and Wrn Null Mice. ( 26447695 )
2015

Variations for Werner Syndrome

UniProtKB/Swiss-Prot genetic disease variations for Werner Syndrome:

71
# Symbol AA change Variation ID SNP ID
1 WRN p.Lys125Asn VAR_026588 rs387906337
2 WRN p.Lys135Glu VAR_026589 rs267607008

ClinVar genetic disease variations for Werner Syndrome:

6 (show all 32)
# Gene Variation Type Significance SNP ID Assembly Location
1 WRN NM_000553.4(WRN): c.2089-3024A> G single nucleotide variant Pathogenic rs281865157 GRCh37 Chromosome 8, 30966107: 30966107
2 WRN NM_000553.5(WRN): c.2179dup (p.Cys727Leufs) duplication Pathogenic rs281865158 GRCh37 Chromosome 8, 30969221: 30969221
3 WRN NM_000553.4(WRN): c.3460-2A> C single nucleotide variant Pathogenic rs281865159 GRCh37 Chromosome 8, 31004878: 31004878
4 WRN NM_000553.4(WRN): c.3590delA (p.Asn1197Thrfs) deletion Pathogenic rs281865160 GRCh37 Chromosome 8, 31007874: 31007874
5 WRN NM_000553.5(WRN): c.561A> G (p.Lys187=) single nucleotide variant Pathogenic rs775802030 GRCh37 Chromosome 8, 30924605: 30924605
6 WRN NM_000553.4(WRN): c.1105C> T (p.Arg369Ter) single nucleotide variant Pathogenic rs17847577 GRCh38 Chromosome 8, 31081132: 31081132
7 WRN NM_000553.4(WRN): c.3686A> T (p.Gln1229Leu) single nucleotide variant Pathogenic rs369158322 GRCh38 Chromosome 8, 31150454: 31150454
8 WRN RECQL2, 1-BP DEL, NT1396 deletion Pathogenic
9 WRN NM_000553.4(WRN): c.1730A> T (p.Lys577Met) single nucleotide variant Pathogenic rs121908448 GRCh37 Chromosome 8, 30948359: 30948359
10 WRN NM_000553.4(WRN): c.3913C> T (p.Arg1305Ter) single nucleotide variant Pathogenic rs121908446 GRCh37 Chromosome 8, 31014977: 31014977
11 WRN NM_000553.4(WRN): c.3493C> T (p.Gln1165Ter) single nucleotide variant Pathogenic rs121908447 GRCh37 Chromosome 8, 31004913: 31004913
12 WRN NM_000553.4(WRN): c.3690_3693delAGAC (p.Asp1231Serfs) deletion Pathogenic rs606231162 GRCh38 Chromosome 8, 31154626: 31154629
13 WRN NM_000553.4(WRN): c.3139-1G> C single nucleotide variant Pathogenic rs113993961 GRCh37 Chromosome 8, 30999196: 30999196
14 WRN NM_000553.5(WRN): c.3915dup (p.Ala1306Serfs) duplication Pathogenic rs587776621 GRCh37 Chromosome 8, 31014979: 31014979
15 WRN NM_000553.5(WRN): c.487_488delGA (p.Asp163Cysfs) deletion Likely pathogenic rs797045118 GRCh37 Chromosome 8, 30922562: 30922563
16 WRN NM_000553.4(WRN): c.15delA (p.Lys5Asnfs) deletion Pathogenic rs878854133 GRCh37 Chromosome 8, 30915978: 30915978
17 WRN NM_000553.5(WRN): c.2546_2547dup (p.Gln850Ilefs) duplication Pathogenic rs878854136 GRCh38 Chromosome 8, 31120340: 31120341
18 WRN NM_000553.4(WRN): c.2959C> T (p.Arg987Ter) single nucleotide variant Pathogenic/Likely pathogenic rs747319628 GRCh38 Chromosome 8, 31132498: 31132498
19 WRN NC_000008.11: g.(?_31150341)_(31157530_?)del deletion Pathogenic GRCh38 Chromosome 8, 31150341: 31157530
20 WRN NM_000553.4(WRN): c.502_503delAA (p.Lys168Alafs) deletion Pathogenic rs1060500056 GRCh38 Chromosome 8, 31065061: 31065062
21 WRN NM_000553.4(WRN): c.1898+2T> G single nucleotide variant Likely pathogenic rs772319506 GRCh38 Chromosome 8, 31091900: 31091900
22 WRN NM_000553.4(WRN): c.2665C> T (p.Arg889Ter) single nucleotide variant Pathogenic rs774765029 GRCh38 Chromosome 8, 31124556: 31124556
23 WRN NM_000553.4(WRN): c.673C> T (p.Arg225Ter) single nucleotide variant Pathogenic rs370324188 GRCh38 Chromosome 8, 31068276: 31068276
24 WRN NC_000008.11: g.(?_31059147)_(31059271_?)del deletion Pathogenic GRCh38 Chromosome 8, 31059147: 31059271
25 WRN NM_000553.5(WRN): c.327T> A (p.Cys109Ter) single nucleotide variant Pathogenic rs371538747 GRCh38 Chromosome 8, 31064406: 31064406
26 WRN NM_000553.5(WRN): c.2103_2104delAC (p.Leu702Tyrfs) deletion Pathogenic GRCh37 Chromosome 8, 30969145: 30969146
27 WRN NM_000553.5(WRN): c.3037_3038delAG (p.Ser1013Leufs) deletion Pathogenic GRCh38 Chromosome 8, 31141499: 31141500
28 WRN NM_000553.5(WRN): c.210-1G> A single nucleotide variant Likely pathogenic rs758988621 GRCh37 Chromosome 8, 30921804: 30921804
29 WRN NM_000553.5(WRN): c.3384-1G> A single nucleotide variant Likely pathogenic rs776963381 GRCh37 Chromosome 8, 31004568: 31004568
30 WRN NM_000553.5(WRN): c.3408dup (p.Ala1137Serfs) duplication Pathogenic GRCh38 Chromosome 8, 31147077: 31147077
31 WRN NM_000553.5(WRN): c.229dup (p.Asp77Glyfs) duplication Pathogenic GRCh37 Chromosome 8, 30921824: 30921824
32 WRN NM_000553.5(WRN): c.2107dup (p.Thr703Asnfs) duplication Pathogenic GRCh37 Chromosome 8, 30969149: 30969149

Expression for Werner Syndrome

Search GEO for disease gene expression data for Werner Syndrome.

Pathways for Werner Syndrome

Pathways related to Werner Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.16 BLM EXO1 FEN1 LMNA MRE11 RPA1
2
Show member pathways
12.76 BLM EXO1 MRE11 RPA1 WRN
3
Show member pathways
12.66 BLM EXO1 FEN1 MRE11 PARP1 POLB
4
Show member pathways
12.64 FEN1 PARP1 POLB RPA1 WRN
5
Show member pathways
12.41 FEN1 MRE11 PARP1 POLB XRCC5
6
Show member pathways
12.4 BLM EXO1 MRE11 RPA1 WRN
7
Show member pathways
12.38 BLM PARP1 RPA1 WRN
8
Show member pathways
12.28 BLM LMNA MRE11 RPA1
9
Show member pathways
12.06 BLM EXO1 MRE11 RPA1 WRN
10
Show member pathways
11.84 BLM EXO1 MRE11 RPA1 WRN
11 11.83 BLM FEN1 LMNA MRE11 RECQL RECQL4
12
Show member pathways
11.69 EXO1 FEN1 RPA1
13
Show member pathways
11.57 BLM HELLS MRE11
14 11.44 BLM MRE11 WRN XRCC5
15 11.02 MRE11 XRCC5
16 10.84 FEN1 MRE11 WRN XRCC5

GO Terms for Werner Syndrome

Cellular components related to Werner Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 BLM DHX9 EXO1 FEN1 HELLS LMNA
2 nucleolus GO:0005730 9.85 BLM DHX9 FEN1 PARP1 WRN XRCC5
3 protein complex GO:0043234 9.8 DHX9 FEN1 PARP1 POLB VCP XRCC5
4 chromosome GO:0005694 9.76 MRE11 RECQL RECQL5 XRCC5
5 PML body GO:0016605 9.58 BLM MRE11 RPA1
6 chromosome, telomeric region GO:0000781 9.56 BLM MRE11 RECQL4 WRN
7 nuclear chromosome, telomeric region GO:0000784 9.55 FEN1 MRE11 PARP1 RPA1 XRCC5
8 nucleoplasm GO:0005654 9.47 BLM DHX9 EXO1 FEN1 LMNA MRE11
9 replication fork GO:0005657 9.43 BLM WRN

Biological processes related to Werner Syndrome according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 DNA replication GO:0006260 9.96 BLM DHX9 EXO1 FEN1 MRE11 POLB
2 regulation of signal transduction by p53 class mediator GO:1901796 9.92 BLM EXO1 MRE11 RPA1 WRN
3 double-strand break repair GO:0006302 9.88 FEN1 MRE11 PARP1 VCP WRN XRCC5
4 nucleic acid phosphodiester bond hydrolysis GO:0090305 9.87 EXO1 FEN1 MRE11 WRN
5 telomere maintenance GO:0000723 9.85 PARP1 RECQL4 RPA1 WRN XRCC5
6 base-excision repair GO:0006284 9.83 FEN1 POLB RECQL4 RPA1 WRN
7 double-strand break repair via homologous recombination GO:0000724 9.81 BLM FEN1 MRE11 PARP1 RECQL RECQL4
8 DNA synthesis involved in DNA repair GO:0000731 9.8 BLM EXO1 MRE11 WRN
9 strand displacement GO:0000732 9.78 BLM EXO1 MRE11 WRN
10 positive regulation of type I interferon production GO:0032481 9.76 DHX9 MRE11 XRCC5
11 t-circle formation GO:0090656 9.73 BLM EXO1 WRN
12 DNA strand renaturation GO:0000733 9.72 BLM RECQL RECQL4
13 telomeric D-loop disassembly GO:0061820 9.71 BLM RECQL4 WRN
14 G-quadruplex DNA unwinding GO:0044806 9.69 BLM DHX9 WRN
15 replication fork processing GO:0031297 9.65 BLM WRN
16 nucleotide-excision repair, preincision complex assembly GO:0006294 9.65 PARP1 RPA1
17 cellular response to gamma radiation GO:0071480 9.65 WRN XRCC5
18 nucleotide-excision repair, DNA gap filling GO:0006297 9.64 POLB RPA1
19 telomere maintenance via semi-conservative replication GO:0032201 9.64 FEN1 RPA1
20 nucleotide-excision repair, DNA incision, 3-to lesion GO:0006295 9.63 PARP1 RPA1
21 DNA-dependent DNA replication GO:0006261 9.63 POLB RPA1
22 nucleotide-excision repair, preincision complex stabilization GO:0006293 9.62 PARP1 RPA1
23 mitotic G2 DNA damage checkpoint GO:0007095 9.62 BLM MRE11
24 error-free translesion synthesis GO:0070987 9.61 RPA1 VCP
25 somatic hypermutation of immunoglobulin genes GO:0016446 9.61 EXO1 POLB
26 DNA recombination GO:0006310 9.61 BLM EXO1 MRE11 RECQL RECQL4 RECQL5
27 DNA double-strand break processing GO:0000729 9.6 BLM MRE11
28 cellular metabolic process GO:0044237 9.59 BLM WRN
29 cellular response to camptothecin GO:0072757 9.58 BLM RECQL5
30 DNA duplex unwinding GO:0032508 9.23 BLM DHX9 MRE11 RECQL RECQL4 RECQL5
31 DNA repair GO:0006281 10.13 BLM EXO1 FEN1 MRE11 PARP1 POLB
32 cellular response to DNA damage stimulus GO:0006974 10.11 BLM EXO1 FEN1 MRE11 PARP1 POLB

Molecular functions related to Werner Syndrome according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 catalytic activity GO:0003824 9.95 BLM EXO1 FEN1 WRN
2 ATPase activity GO:0016887 9.92 BLM DHX9 VCP WRN
3 nuclease activity GO:0004518 9.88 EXO1 FEN1 MRE11 WRN
4 double-stranded DNA binding GO:0003690 9.87 DHX9 FEN1 MRE11 XRCC5
5 damaged DNA binding GO:0003684 9.83 FEN1 POLB RPA1 XRCC5
6 single-stranded DNA binding GO:0003697 9.82 BLM DHX9 RPA1
7 exonuclease activity GO:0004527 9.81 EXO1 FEN1 MRE11 WRN
8 endonuclease activity GO:0004519 9.8 EXO1 FEN1 MRE11
9 helicase activity GO:0004386 9.76 BLM DHX9 HELLS RECQL RECQL4 RECQL5
10 ATP-dependent DNA helicase activity GO:0004003 9.73 BLM DHX9 MRE11 RECQL WRN XRCC5
11 ATP-dependent helicase activity GO:0008026 9.72 BLM RECQL RECQL4 RECQL5 WRN
12 DNA helicase activity GO:0003678 9.71 BLM RECQL RECQL5 WRN
13 annealing helicase activity GO:0036310 9.67 BLM RECQL RECQL4
14 3-5 exonuclease activity GO:0008408 9.65 MRE11 WRN
15 four-way junction DNA binding GO:0000400 9.65 BLM WRN
16 bubble DNA binding GO:0000405 9.65 BLM RECQL4 WRN
17 RNA-DNA hybrid ribonuclease activity GO:0004523 9.64 EXO1 FEN1
18 5-3 exonuclease activity GO:0008409 9.63 EXO1 FEN1
19 G-quadruplex DNA binding GO:0051880 9.62 BLM WRN
20 Y-form DNA binding GO:0000403 9.61 BLM WRN
21 telomeric D-loop binding GO:0061821 9.61 BLM RECQL4 WRN
22 telomeric G-quadruplex DNA binding GO:0061849 9.59 BLM WRN
23 8-hydroxy-2-deoxyguanosine DNA binding GO:1905773 9.58 BLM WRN
24 flap endonuclease activity GO:0048256 9.56 EXO1 FEN1
25 forked DNA-dependent helicase activity GO:0061749 9.55 BLM WRN
26 four-way junction helicase activity GO:0009378 9.35 BLM RECQL RECQL4 RECQL5 WRN
27 ATP-dependent 3-5 DNA helicase activity GO:0043140 9.1 BLM DHX9 RECQL RECQL4 RECQL5 WRN
28 protein binding GO:0005515 10.49 BLM DHX9 EXO1 FEN1 HELLS LMNA
29 DNA binding GO:0003677 10.2 BLM DHX9 EXO1 FEN1 MRE11 PARP1
30 ATP binding GO:0005524 10.19 BLM DHX9 HELLS RECQL RECQL4 RECQL5
31 hydrolase activity GO:0016787 10.11 BLM DHX9 EXO1 FEN1 HELLS MRE11
32 nucleic acid binding GO:0003676 10.08 BLM DHX9 RECQL RECQL5 RPA1 WRN

Sources for Werner Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....